Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

FOLD

Amicus Therapeutics Inc

Feb 10 • 04:00PM ET

14.30

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT BMRN REGN CRSP EDIT PFE QURE AGIO BLUE

| Held by: VTI XBI IWM VB VBK VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.04	Insider Own	1.77%	Shs Outstand	308.50M	Perf Week	0.14%
Market Cap	4.49B	Forward P/E	50.05	EPS next Y	0.29	Insider Trans	-7.60%	Shs Float	308.16M	Perf Month	0.14%
Enterprise Value	4.66B	PEG	-	EPS next Q	0.07	Inst Own	97.41%	Short Float	5.83%	Perf Quarter	61.22%
Income	-14.06M	P/S	7.49	EPS this Y	92.06%	Inst Trans	-3.29%	Short Ratio	1.64	Perf Half Y	114.88%
Sales	598.70M	P/B	19.15	EPS next Y	2099.96%	ROA	-1.70%	Short Interest	17.96M	Perf YTD	0.42%
Book/sh	0.75	P/C	17.00	EPS next 5Y	-	ROE	-6.87%	52W High	14.38 -0.56%	Perf Year	48.34%
Cash/sh	0.84	P/FCF	462.95	EPS past 3/5Y	41.55% 34.10%	ROIC	-2.12%	52W Low	5.51 159.53%	Perf 3Y	13.67%
Dividend Est.	-	EV/EBITDA	110.75	Sales past 3/5Y	20.03% 23.72%	Gross Margin	88.50%	Volatility	0.22% 0.24%	Perf 5Y	-26.93%
Dividend TTM	-	EV/Sales	7.79	EPS Y/Y TTM	87.30%	Oper. Margin	5.77%	ATR (14)	0.08	Perf 10Y	165.31%
Dividend Ex-Date	-	Quick Ratio	2.09	Sales Y/Y TTM	21.28%	Profit Margin	-2.35%	RSI (14)	79.35	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.99	EPS Q/Q	352.49%	SMA20	0.01%	Beta	0.43	Target Price	14.50
Payout	-	Debt/Eq	1.92	Sales Q/Q	19.46%	SMA50	9.58%	Rel Volume	0.41	Prev Close	14.30
Employees	499	LT Debt/Eq	1.88	Earnings	Nov 04 BMO	SMA200	63.43%	Avg Volume	10.92M	Price	14.30
IPO	May 31, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	55.44% 2.02%	Trades		Volume	4,437,776	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-26	Downgrade	Jefferies	Buy → Hold	$14.50
Dec-29-25	Downgrade	Leerink Partners	Outperform → Market Perform	$14.50
Dec-22-25	Downgrade	TD Cowen	Buy → Hold	$14.50
Dec-17-25	Initiated	Citigroup	Buy	$17
Sep-18-25	Upgrade	Needham	Hold → Buy	$14
Jul-17-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$108
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $12
Sep-06-24	Initiated	Jefferies	Buy	$18
May-30-24	Initiated	Wells Fargo	Overweight	$18
May-14-24	Upgrade	Guggenheim	Neutral → Buy	$13
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15 → $20
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$14
Apr-13-22	Resumed	Goldman	Neutral	$11
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$12 → $16
Nov-15-21	Upgrade	Stifel	Hold → Buy	$12 → $16
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight	$16
Jul-19-21	Resumed	BTIG Research	Buy	$15
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy	$16
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$17

Show Previous Ratings

Feb-03-26 08:00AM	Amicus Therapeutics Presents New Long-term Data for both Galafold (migalastat) and POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at the 22nd Annual WORLDSymposium 2026 (GlobeNewswire)
Feb-02-26 09:29AM	Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments (Insider Monkey)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
08:00AM	Loading…
08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More (24/7 Wall St.)
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
08:01AM	Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
11:01AM	FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
Jan-15-26 11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
10:26AM	Loading…
10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
06:47AM	One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit (24/7 Wall St.)
Jan-14-26 10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
Jan-13-26 01:28PM	ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook (Zacks)
09:19AM	Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes (Zacks)
Jan-12-26 02:07PM	KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives (Zacks)
11:20AM	MDGL Secures Exclusive Global Right for MASH Treatment From PFE (Zacks)
10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
09:33AM	Exelixis Posts Preliminary '25 Results, Issues '26 Outlook (Zacks)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
09:17AM	Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress (Zacks)
Jan-08-26 12:49PM	Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
09:44AM	KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? (Zacks)
08:50AM	Loading…
08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks)
Jan-07-26 09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks)
Jan-06-26 11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
11:15AM	Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings? (Zacks)
10:50AM	Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-02-26 01:13PM	When healthcare M&A hits the cold chain (FreightWaves)
Dec-30-25 10:19AM	Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-23-25 06:45PM	Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-22-25 12:27PM	BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push (Pharmaceutical Technology)
12:15PM	A $4.8 Billion Reason to Buy BioMarin Stock Today (Barchart)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly)
09:29AM	Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up (Zacks)
Dec-20-25 08:12AM	Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger (Insider Monkey)
Dec-19-25 04:32PM	Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal) +30.21%
04:17PM	BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus (Investor's Business Daily)
12:41PM	Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play (GuruFocus.com)
12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
11:57AM	BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
11:01AM	Stocks to Watch Friday: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal)
10:55AM	BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. (Barrons.com)
09:38AM	Stocks to Watch Friday: Nike, Oracle, FedEx, Sony (The Wall Street Journal)
09:33AM	BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal (Investor's Business Daily)
08:13AM	BioMarin to Buy Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
07:45AM	BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook (PR Newswire)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-16-25 10:30AM	FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
08:53AM	GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal (Zacks)
Dec-15-25 09:59AM	RCUS Stock Down on Decision to Discontinue GILD Partnered Study (Zacks)
Dec-13-25 07:05AM	Amicus Therapeutics (FOLD) Soars to 52-Week High on 'Strong Buy' Reco (Insider Monkey)
Dec-12-25 09:55AM	Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High? (Zacks) +6.57%
Dec-09-25 01:48PM	The Best Cheap Stocks Under $10 to Buy in December and 2026 (Zacks)
Dec-08-25 08:23AM	Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus (Zacks)
Dec-05-25 12:20PM	Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock (Zacks)
09:57AM	Can Galafold Continue to Drive Amicus' Top Line in 2026? (Zacks)
Dec-04-25 11:30AM	Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue? (Zacks)
10:29AM	BMY Gains on News of Continuation of Alzheimer's Disease Study (Zacks)
Dec-02-25 02:20PM	BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business (Zacks)
Nov-26-25 09:55AM	Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet (Zacks)
Nov-25-25 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
Nov-24-25 01:53PM	BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-19-25 08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
Nov-14-25 08:11AM	GILD's Investigational Regimen for HIV Treatment Meets Primary Goal (Zacks)
Nov-13-25 01:46PM	Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth? (Zacks)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
Nov-10-25 08:16PM	Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results (Insider Monkey)
09:55AM	Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade (Zacks)
01:44AM	Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets (Zacks)
Nov-07-25 10:40AM	Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns (Zacks)
Nov-06-25 10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
08:27AM	ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales (Zacks)
Nov-05-25 10:52AM	EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales (Zacks)
10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
10:08AM	Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues (Zacks)
09:30AM	Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics (Zacks)
Nov-04-25 04:07PM	Amicus Therapeutics Inc (FOLD) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:29AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Bradley L	President and CEO	Jan 20 '26	Option Exercise	6.10	75,000	457,500	1,096,180	Jan 22 07:26 PM
Campbell Bradley L	President and CEO	Jan 20 '26	Sale	14.31	75,000	1,073,182	1,021,180	Jan 22 07:26 PM
BRADLEY CAMPBELL	Director	Jan 20 '26	Proposed Sale	14.33	75,000	1,074,750		Jan 20 04:26 PM
Clark David Michael	Chief People Officer	Dec 19 '25	Sale	14.17	25,642	363,380	245,690	Dec 23 04:16 PM
DAVID CLARK	Officer	Dec 19 '25	Proposed Sale	10.89	25,642	279,241		Dec 19 04:22 PM
Campbell Bradley L	President and CEO	Dec 15 '25	Option Exercise	9.03	70,426	635,947	1,207,708	Dec 17 06:21 PM
Campbell Bradley L	President and CEO	Dec 15 '25	Sale	10.86	77,926	846,011	1,129,782	Dec 17 06:21 PM
Clark David Michael	Chief People Officer	Dec 15 '25	Sale	11.00	25,643	282,073	271,332	Dec 17 06:19 PM
BRADLEY CAMPBELL	Director	Dec 15 '25	Proposed Sale	10.55	77,926	822,119		Dec 15 04:32 PM
DAVID CLARK	Officer	Dec 15 '25	Proposed Sale	10.55	25,643	270,534		Dec 15 04:17 PM
Campbell Bradley L	President and CEO	Dec 01 '25	Option Exercise	9.03	14,587	131,721	1,151,869	Dec 03 08:11 PM
Campbell Bradley L	President and CEO	Dec 01 '25	Sale	10.01	14,587	146,011	1,137,282	Dec 03 08:11 PM
BRADLEY CAMPBELL	Director	Dec 01 '25	Proposed Sale	9.93	14,587	144,849		Dec 01 04:19 PM
Castelli Jeff	Chief Development Officer	Nov 24 '25	Option Exercise	9.03	50,000	451,500	515,476	Nov 26 09:18 PM
Castelli Jeff	Chief Development Officer	Nov 24 '25	Sale	10.16	76,158	773,659	439,318	Nov 26 09:18 PM
Clark David Michael	Chief People Officer	Nov 24 '25	Sale	10.10	25,643	258,933	296,975	Nov 26 09:17 PM
Campbell Bradley L	President and CEO	Nov 24 '25	Option Exercise	9.03	14,587	131,721	1,151,869	Nov 26 09:17 PM
Campbell Bradley L	President and CEO	Nov 24 '25	Sale	10.04	14,587	146,522	1,137,282	Nov 26 09:17 PM
Rosenberg Ellen	Chief Legal Officer	Nov 24 '25	Option Exercise	5.80	36,000	208,930	543,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 25 '25	Option Exercise	5.13	36,000	184,680	543,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 26 '25	Option Exercise	5.13	23,621	121,176	531,331	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 24 '25	Sale	10.06	36,000	362,268	507,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 25 '25	Sale	10.00	36,000	360,000	507,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 26 '25	Sale	10.00	23,621	236,210	507,710	Nov 26 09:16 PM
ELLEN ROSENBERG	Officer	Nov 26 '25	Proposed Sale	9.87	23,621	233,139		Nov 26 04:18 PM
ELLEN ROSENBERG	Officer	Nov 25 '25	Proposed Sale	9.89	36,000	356,040		Nov 25 04:27 PM
JEFFREY CASTELLI	Officer	Nov 24 '25	Proposed Sale	9.56	76,158	728,070		Nov 24 04:25 PM
DAVID CLARK	Officer	Nov 24 '25	Proposed Sale	9.56	25,643	245,147		Nov 24 04:24 PM
BRADLEY CAMPBELL	Director	Nov 24 '25	Proposed Sale	9.56	14,587	139,452		Nov 24 04:24 PM
ELLEN ROSENBERG	Officer	Nov 24 '25	Proposed Sale	9.56	36,000	344,160		Nov 24 04:23 PM
Clark David Michael	Chief People Officer	Nov 04 '25	Sale	9.51	25,643	243,860	322,618	Nov 05 04:05 PM
DAVID CLARK	Officer	Nov 04 '25	Proposed Sale	8.86	25,643	227,197		Nov 04 04:33 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Option Exercise	9.03	400	3,612	1,151,057	Feb 21 07:27 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Sale	10.00	400	4,000	1,150,657	Feb 21 07:27 PM
BRADLEY CAMPBELL	Director	Feb 19 '25	Proposed Sale	9.85	400	3,940		Feb 19 04:36 PM

Open in Screener

VRTX

Vertex Pharmaceuticals, Inc

Feb 10 • 04:00PM ET

463.48

-7.39 -1.57 %

Healthcare • Biotechnology • USA • NASD

VRTX Vertex Pharmaceuticals, Inc daily Stock Chart

Peers: BIIB GILD AMGN REGN MRNA INCY ALNY NBIX EXEL

| Held by: VTI VOO QQQ IVV SPY VUG XLV IBB IWF QQQM

Index	NDX, S&P 500	P/E	32.67	EPS (ttm)	14.19	Insider Own	0.34%	Shs Outstand	253.95M	Perf Week	-0.46%
Market Cap	117.59B	Forward P/E	23.33	EPS next Y	19.87	Insider Trans	-16.74%	Shs Float	252.86M	Perf Month	-0.08%
Enterprise Value	113.13B	PEG	-	EPS next Q	5.11	Inst Own	94.56%	Short Float	1.75%	Perf Quarter	13.19%
Income	3.68B	P/S	10.02	EPS this Y	4299.52%	Inst Trans	-1.12%	Short Ratio	3.15	Perf Half Y	23.77%
Sales	11.73B	P/B	6.80	EPS next Y	7.53%	ROA	15.60%	Short Interest	4.42M	Perf YTD	2.23%
Book/sh	68.20	P/C	18.68	EPS next 5Y	-	ROE	22.31%	52W High	519.68 -10.81%	Perf Year	-1.38%
Cash/sh	24.81	P/FCF	35.24	EPS past 3/5Y	- -	ROIC	19.19%	52W Low	362.50 27.86%	Perf 3Y	55.84%
Dividend Est.	-	EV/EBITDA	23.83	Sales past 3/5Y	13.04% 21.61%	Gross Margin	86.29%	Volatility	3.21% 2.75%	Perf 5Y	118.08%
Dividend TTM	-	EV/Sales	9.64	EPS Y/Y TTM	872.81%	Oper. Margin	38.76%	ATR (14)	12.61	Perf 10Y	467.09%
Dividend Ex-Date	-	Quick Ratio	2.00	Sales Y/Y TTM	10.53%	Profit Margin	31.32%	RSI (14)	49.80	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	2.36	EPS Q/Q	4.95%	SMA20	-0.08%	Beta	0.32	Target Price	522.84
Payout	-	Debt/Eq	0.11	Sales Q/Q	12.27%	SMA50	1.24%	Rel Volume	1.50	Prev Close	470.87
Employees	6100	LT Debt/Eq	0.11	Earnings	Feb 12 AMC	SMA200	6.32%	Avg Volume	1.40M	Price	463.48
IPO	Jul 24, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.96% 0.55%	Trades		Volume	2,112,642	Change	-1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$606
Jan-22-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$546
Jan-12-26	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-07-26	Resumed	UBS	Buy	$535
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$548
Dec-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$516
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$495
Sep-25-25	Upgrade	Leerink Partners	Market Perform → Outperform	$456
Sep-03-25	Initiated	Raymond James	Mkt Perform
Aug-06-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$460
May-07-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-06-25	Downgrade	Leerink Partners	Outperform → Market Perform	$503
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$535
Feb-12-25	Upgrade	Canaccord Genuity	Sell → Hold	$408 → $424
Feb-11-25	Upgrade	Canaccord Genuity	Sell → Hold
Jan-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$460
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$600 → $535
Dec-19-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$500 → $550
Nov-14-24	Initiated	Citigroup	Buy	$575

Show Previous Ratings

Feb-10-26 10:03PM	Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect (StockStory)
11:10AM	LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal (Zacks)
10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
Feb-09-26 11:38AM	Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? (Zacks)
11:30AM	Robinhood, AppLovin, Rivian and More Stocks With Earnings This Week (Benzinga)
09:15AM	Loading…
09:15AM	Seeking Clues to Vertex (VRTX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
08:55AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Feb-05-26 07:28PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
10:00AM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-04-26 10:28AM	Software stocks take hit on AI. Is Wall Street worried of a bubble? (Yahoo Finance Video)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Feb-03-26 02:57PM	These Are The Worst 25 Stocks to Own in February (Schaeffer's Research)
09:00AM	Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? (Zacks)
08:30AM	Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
08:30AM	CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
11:31AM	Loading…
Jan-31-26 11:31AM	Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story (Insider Monkey)
Jan-30-26 05:50PM	Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today (Zacks)
11:15AM	Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season (Investor's Business Daily)
Jan-29-26 05:19PM	Top Analyst Reports for Applied Materials, Linde & Abbott (Zacks)
09:20AM	Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals (Motley Fool)
07:00AM	Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs (Business Wire)
Jan-28-26 11:34PM	1 Healthcare Stock to Consider Right Now and 2 We Brush Off (StockStory)
07:31AM	Here's Why Hardman Johnston Global Equity Strategy Sold Vertex Pharmaceuticals (VRTX) (Insider Monkey)
Jan-26-26 10:16AM	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets (PR Newswire)
Jan-23-26 09:30AM	Wall Street Analysts Think Vertex (VRTX) Is a Good Investment: Is It? (Zacks)
Jan-22-26 06:00PM	Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider (Zacks)
12:07AM	Why Is Vertex Pharmaceuticals (VRTX) Stock Trending Overnight? (Benzinga)
Jan-21-26 10:35PM	Reflecting On Therapeutics Stocks' Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) (StockStory)
Jan-20-26 04:00PM	Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th (Business Wire)
Jan-19-26 10:31PM	Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks (StockStory)
07:49AM	Loading…
07:49AM	Bernstein Names Vertex (VRTX) a "Top Biotech Pick" for 2026 Following Upgrade to Outperform (Insider Monkey)
05:04AM	My Forever Portfolio: 5 Stocks I Don't Plan on Ever Selling (Motley Fool)
Jan-16-26 08:54AM	Implied Volatility Surging for Vertex Pharmaceuticals Stock Options (Zacks)
Jan-15-26 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why (Zacks)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jan-14-26 11:35AM	Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 (Motley Fool)
Jan-13-26 10:25AM	JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease (Pharmaceutical Technology)
09:31AM	Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report (Barchart)
Jan-12-26 12:10PM	Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:05AM	Here's What Lifted Vertex Pharmaceuticals (VRTX) in Q4 (Insider Monkey)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Jan-11-26 05:00PM	Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings (Business Wire)
06:01AM	The Best Stocks to Invest $50,000 in Right Now (Motley Fool)
Jan-09-26 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts (Zacks)
09:50AM	Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 (Motley Fool)
Jan-08-26 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jan-07-26 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:00AM	Bank of America Says These 2 Healthcare Stocks Are Top Ideas for 1Q26 (TipRanks)
Jan-06-26 05:00PM	Top Research Reports for JPMorgan Chase, RTX & Applied Materials (Zacks)
03:06PM	Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why (StockStory)
Jan-05-26 08:35PM	My 10 Top Stocks to Buy to Start the New Year Off Right (Motley Fool)
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
11:12AM	BofA unveils its top 10 U.S. ideas for Q1 2026 (Investing.com)
Jan-01-26 06:05AM	The Best Stocks to Invest $1,000 in to Start the New Year Off Right (Motley Fool)
Dec-30-25 05:50PM	Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know (Zacks)
04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
09:50AM	Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock (Zacks)
08:20AM	2 Growth Stocks to Buy For 2026 and Beyond (Motley Fool)
08:10AM	Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink (TipRanks)
Dec-29-25 08:42AM	Should You Be Confident in Vertex Pharmaceuticals Incorporated's (VRTX) Long-Term Outlook? (Insider Monkey)
Dec-28-25 01:33PM	3 Supercharged Growth Stocks to Buy and Hold Into the 2030s (Motley Fool)
Dec-27-25 10:30AM	Forget Moderna Stock, This is a Much Better Buy (Motley Fool)
Dec-24-25 04:35AM	Is CRISPR Therapeutics Stock Yesterday's News? (Motley Fool)
Dec-23-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Dec-22-25 04:00PM	Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12 (Business Wire)
Dec-19-25 07:05AM	Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? (Motley Fool)
Dec-17-25 11:02PM	2 Reasons to Watch VRTX and 1 to Stay Cautious (StockStory)
05:50PM	Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Dec-15-25 11:30AM	12 Days of Investing: My Top 12 Stocks to Buy Before 2026 (Motley Fool)
Dec-12-25 01:05PM	2 Healthcare Stocks to Buy Ahead of the New Year (Motley Fool)
09:00AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
03:04AM	3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term (Motley Fool)
Dec-11-25 05:00AM	Earnings update: Zoom, Virgin Galactic, Nvidia, Warner Bros Discovery and more (CFO.com)
Dec-09-25 09:56AM	Stock Market Today: Dow Up Ahead Of Fed Meeting; Nvidia Falls Despite Trump Comments (Live Coverage) (Investor's Business Daily)
Dec-08-25 09:50AM	Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-06-25 07:35PM	Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? (Motley Fool)
07:01AM	Vertex Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions (Business Wire)
Dec-05-25 11:30AM	Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 11:22PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
03:30PM	1 Reason I'll Never Sell Vertex Pharmaceuticals Stock (Motley Fool)
09:34AM	Harding Loevner Global Equity's Views on Vertex Pharmaceuticals Incorporated (VRTX) (Insider Monkey)
Dec-03-25 04:51PM	Top Stock Reports for Procter & Gamble, Lam Research & Texas Instruments (Zacks) +6.92%
02:11PM	Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today (StockStory)
11:30AM	Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report? (Zacks)
09:35AM	Oracle initiated, Uber upgraded: Wall Street's top analyst calls (The Fly)
09:01AM	Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
06:15AM	2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term (Motley Fool)
Dec-01-25 07:45PM	3 Top Stocks to Buy in December (Motley Fool)
09:00AM	Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock (Zacks)
Nov-28-25 06:25AM	Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq? (Barchart)
Nov-27-25 06:31AM	Where Will Vertex Pharmaceuticals Be in 5 Years (Motley Fool)
Nov-26-25 02:49PM	What Do Analysts Think About Vertex Pharmaceuticals (VRTX)? (Insider Monkey)
Nov-23-25 10:28AM	2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon (Motley Fool)
Nov-21-25 06:56PM	Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why (StockStory)
Nov-20-25 06:48PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
09:53AM	2 Inflation-Proof Growth Stocks That Could Outperform the Market (Motley Fool)
Nov-19-25 04:00PM	Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3 (Business Wire)
Nov-18-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
07:54AM	Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings (Barchart)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Jan 07 '26	Sale	474.99	4,500	2,137,455	42,293	Jan 09 04:05 PM
WAGNER CHARLES F JR	EVP, CO & FO	Jan 06 '26	Option Exercise	189.38	9,532	1,805,170	47,257	Jan 08 04:04 PM
WAGNER CHARLES F JR	EVP, CO & FO	Jan 06 '26	Sale	461.00	9,532	4,394,252	37,725	Jan 08 04:04 PM
Tatsis Ourania	Officer	Jan 07 '26	Proposed Sale	474.99	4,500	2,137,455		Jan 07 10:31 AM
WAGNER CHARLES F JR	Officer	Jan 06 '26	Proposed Sale	461.00	9,532	4,394,252		Jan 06 11:16 AM
WAGNER CHARLES F JR	EVP, CO & FO	Dec 03 '25	Sale	456.00	14,000	6,384,000	37,725	Dec 05 04:16 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Dec 03 '25	Sale	449.99	4,500	2,024,955	46,793	Dec 05 04:12 PM
LEIDEN JEFFREY M	Executive Chairman	Dec 03 '25	Option Exercise	86.52	63,781	5,518,332	87,807	Dec 05 04:10 PM
LEIDEN JEFFREY M	Executive Chairman	Dec 04 '25	Option Exercise	91.05	1	91	24,027	Dec 05 04:10 PM
LEIDEN JEFFREY M	Executive Chairman	Dec 03 '25	Sale	449.20	63,781	28,650,337	24,026	Dec 05 04:10 PM
Biller Jonathan	EVP and Chief Legal Officer	Dec 03 '25	Sale	449.00	347	155,803	15,306	Dec 05 04:06 PM
JEFFREY M LEIDEN	Director	Dec 03 '25	Proposed Sale	433.15	63,781	27,626,740		Dec 03 04:34 PM
WAGNER CHARLES F JR	Officer	Dec 03 '25	Proposed Sale	461.00	7,000	3,227,000		Dec 03 01:01 PM
WAGNER CHARLES F JR	Officer	Dec 03 '25	Proposed Sale	451.00	7,000	3,157,000		Dec 03 11:24 AM
Tatsis Ourania	Officer	Dec 03 '25	Proposed Sale	449.99	4,500	2,024,955		Dec 03 11:00 AM
Biller Jonathan	Officer	Dec 03 '25	Proposed Sale	449.00	347	155,803		Dec 03 10:52 AM
CARNEY LLOYD	Director	Nov 20 '25	Proposed Sale	426.36	800	341,088		Nov 20 10:27 AM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Nov 17 '25	Sale	434.58	2,500	1,086,450	16,852	Nov 19 04:06 PM
LEIDEN JEFFREY M	Executive Chairman	Nov 14 '25	Option Exercise	87.69	53,604	4,700,491	77,630	Nov 17 04:12 PM
LEIDEN JEFFREY M	Executive Chairman	Nov 13 '25	Option Exercise	91.05	19,688	1,792,592	43,714	Nov 17 04:12 PM
LEIDEN JEFFREY M	Executive Chairman	Nov 14 '25	Sale	440.72	53,604	23,624,306	24,026	Nov 17 04:12 PM
LEIDEN JEFFREY M	Executive Chairman	Nov 13 '25	Sale	440.27	19,688	8,668,014	24,026	Nov 17 04:12 PM
Atkinson Edward Morrow III	Officer	Nov 17 '25	Proposed Sale	434.58	2,500	1,086,450		Nov 17 10:50 AM
JEFFREY M LEIDEN	Director	Nov 14 '25	Proposed Sale	434.52	53,604	23,292,010		Nov 14 04:25 PM
JEFFREY M LEIDEN	Director	Nov 13 '25	Proposed Sale	434.19	19,688	8,548,333		Nov 13 04:28 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '25	Sale	404.21	694	280,522	15,653	Oct 03 04:07 PM
Biller Jonathan	Officer	Oct 02 '25	Proposed Sale	404.21	694	280,522		Oct 02 10:39 AM
Bhatia Sangeeta N.	Director	Aug 27 '25	Sale	386.69	266	102,860	4,565	Aug 29 04:02 PM
Bhatia Sangeeta N.	Director	Aug 27 '25	Proposed Sale	386.69	266	102,860		Aug 27 09:38 AM
Kewalramani Reshma	CEO & President	Aug 06 '25	Buy	389.58	10,000	3,895,768	115,968	Aug 07 04:23 PM
SACHS BRUCE I	Director	Aug 06 '25	Buy	389.68	5,000	1,948,416	45,000	Aug 07 04:19 PM
LR 2019 Benefit Trust	Director	May 21 '25	Proposed Sale	447.18	170	76,021		May 21 04:58 PM
SR 2019 Benefit Trust	Director	May 21 '25	Proposed Sale	447.18	170	76,021		May 21 04:58 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	May 15 '25	Sale	424.69	52	22,084	23,281	May 19 05:07 PM
ALTSHULER DAVID	Officer	May 15 '25	Proposed Sale	424.69	52	22,084		May 15 10:36 AM
Bhatia Sangeeta N.	Director	May 02 '25	Sale	505.86	400	202,344	4,831	May 05 04:14 PM
Bhatia Sangeeta N.	Director	May 02 '25	Proposed Sale	505.86	400	202,344		May 02 09:47 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 13 '25	Sale	510.00	3,231	1,647,810	23,281	Mar 17 04:09 PM
ALTSHULER DAVID	Officer	Mar 13 '25	Proposed Sale	510.00	3,231	1,647,810		Mar 13 11:10 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 10 '25	Sale	500.00	3,298	1,649,000	51,671	Mar 12 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 10 '25	Sale	499.99	3,242	1,620,968	51,239	Mar 12 04:10 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 10 '25	Sale	500.00	3,231	1,615,500	26,512	Mar 12 04:08 PM
Tatsis Ourania	Officer	Mar 10 '25	Proposed Sale	499.99	3,242	1,620,968		Mar 10 01:58 PM
WAGNER CHARLES F JR	Officer	Mar 10 '25	Proposed Sale	500.00	3,298	1,649,000		Mar 10 01:02 PM
ALTSHULER DAVID	Officer	Mar 10 '25	Proposed Sale	500.00	3,231	1,615,500		Mar 10 12:42 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 04 '25	Sale	485.49	4,058	1,970,118	54,481	Mar 06 04:08 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 03 '25	Sale	490.00	3,231	1,583,190	29,743	Mar 05 04:08 PM
Tatsis Ourania	Officer	Mar 04 '25	Proposed Sale	485.49	4,058	1,970,118		Mar 04 01:39 PM
ALTSHULER DAVID	Officer	Mar 03 '25	Proposed Sale	490.00	3,231	1,583,190		Mar 03 04:17 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 27 '25	Sale	475.34	530	251,930	58,539	Feb 28 04:48 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 27 '25	Sale	475.34	2,650	1,259,651	19,352	Feb 28 04:36 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 27 '25	Sale	480.00	1,272	610,560	32,974	Feb 28 04:23 PM
ALTSHULER DAVID	Officer	Feb 27 '25	Proposed Sale	480.00	1,272	610,560		Feb 27 11:20 AM
Atkinson Edward Morrow III	Officer	Feb 27 '25	Proposed Sale	475.34	2,650	1,259,651		Feb 27 10:18 AM
Tatsis Ourania	Officer	Feb 27 '25	Proposed Sale	475.34	530	251,930		Feb 27 10:14 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 25 '25	Sale	480.95	354	170,256	64,031	Feb 26 04:15 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 25 '25	Sale	480.95	1,767	849,839	24,484	Feb 26 04:09 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 25 '25	Sale	480.95	884	425,160	9,086	Feb 26 04:06 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 25 '25	Sale	480.95	848	407,846	40,200	Feb 26 04:04 PM
Tatsis Ourania	Officer	Feb 25 '25	Proposed Sale	480.95	354	170,256		Feb 25 11:38 AM
ALTSHULER DAVID	Officer	Feb 25 '25	Proposed Sale	480.95	848	407,846		Feb 25 11:13 AM
Atkinson Edward Morrow III	Officer	Feb 25 '25	Proposed Sale	480.95	1,767	849,839		Feb 25 10:59 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 20 '25	Sale	480.00	1,111	533,280	45,019	Feb 24 04:07 PM
ALTSHULER DAVID	Officer	Feb 20 '25	Proposed Sale	480.00	1,111	533,280		Feb 20 03:45 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 18 '25	Sale	455.06	244	111,035	67,695	Feb 19 04:36 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 18 '25	Sale	455.06	1,657	754,034	17,606	Feb 19 04:28 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 18 '25	Sale	455.06	671	305,345	10,798	Feb 19 04:21 PM
Tatsis Ourania	Officer	Feb 18 '25	Proposed Sale	455.06	244	111,035		Feb 18 11:34 AM
Biller Jonathan	Officer	Feb 18 '25	Proposed Sale	455.06	1,657	754,034		Feb 18 11:29 AM

FOLD

Amicus Therapeutics Inc

VRTX

Vertex Pharmaceuticals, Inc

Upgrade your FINVIZ experience